NanoSphere Health Sciences Inc. (NSHSF)
USD 0.04
(-60.0%)
USD 0.04
(-60.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -228.12 Thousand USD | 19.03% |
| 2022 | -281.75 Thousand USD | 20.92% |
| 2021 | -356.27 Thousand USD | 39.74% |
| 2020 | -591.22 Thousand USD | 82.96% |
| 2019 | -3.46 Million USD | 23.17% |
| 2018 | -4.51 Million USD | 54.44% |
| 2017 | -9.9 Million USD | -1512.16% |
| 2016 | -614.68 Thousand USD | -360.03% |
| 2015 | -133.61 Thousand USD | 39.17% |
| 2014 | -219.63 Thousand USD | 96.59% |
| 2013 | -6.45 Million USD | -72.88% |
| 2012 | -3.73 Million USD | 58.79% |
| 2011 | -9.05 Million USD | -4501.81% |
| 2010 | -196.71 Thousand USD | -221.22% |
| 2009 | 162.27 Thousand USD | 103.14% |
| 2008 | -5.16 Million USD | -435.54% |
| 2007 | -965.34 Thousand USD | -2998.46% |
| 2006 | -31.15 Thousand USD | -22.82% |
| 2005 | -25.36 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -41.1 Thousand USD | 27.19% |
| 2024 Q2 | -61.04 Thousand USD | -48.53% |
| 2023 FY | -232.31 Thousand USD | 17.55% |
| 2023 Q3 | -41.47 Thousand USD | 46.93% |
| 2023 Q4 | -56.46 Thousand USD | -36.13% |
| 2023 Q1 | -53.55 Thousand USD | 42.72% |
| 2023 Q2 | -78.15 Thousand USD | -45.91% |
| 2022 Q3 | -35.2 Thousand USD | 57.64% |
| 2022 FY | -281.75 Thousand USD | 20.92% |
| 2022 Q2 | -83.12 Thousand USD | -18.89% |
| 2022 Q1 | -69.92 Thousand USD | -137.29% |
| 2022 Q4 | -93.49 Thousand USD | -165.55% |
| 2021 Q1 | -66.63 Thousand USD | 62.87% |
| 2021 Q2 | -127.3 Thousand USD | -91.05% |
| 2021 Q3 | -349.83 Thousand USD | -174.81% |
| 2021 FY | -356.27 Thousand USD | 39.74% |
| 2021 Q4 | 187.5 Thousand USD | 153.6% |
| 2020 FY | -591.22 Thousand USD | 82.96% |
| 2020 Q1 | -235.28 Thousand USD | 82.48% |
| 2020 Q2 | -111.64 Thousand USD | 52.55% |
| 2020 Q3 | -64.83 Thousand USD | 41.93% |
| 2020 Q4 | -179.46 Thousand USD | -176.82% |
| 2019 Q2 | -525.75 Thousand USD | 27.88% |
| 2019 Q4 | -1.34 Million USD | -54.1% |
| 2019 FY | -3.46 Million USD | 23.17% |
| 2019 Q1 | -728.95 Thousand USD | 64.59% |
| 2019 Q3 | -871.32 Thousand USD | -65.73% |
| 2018 FY | -4.51 Million USD | 54.44% |
| 2018 Q1 | -995.18 Thousand USD | 89.75% |
| 2018 Q4 | -2.05 Million USD | -215.88% |
| 2018 Q3 | -651.69 Thousand USD | 19.47% |
| 2018 Q2 | -809.28 Thousand USD | 18.68% |
| 2017 FY | -9.9 Million USD | -1512.16% |
| 2017 Q4 | -9.71 Million USD | -10805.63% |
| 2017 Q2 | -32.55 Thousand USD | 53.0% |
| 2017 Q1 | -69.27 Thousand USD | 19.22% |
| 2017 Q3 | -89.05 Thousand USD | -173.52% |
| 2016 Q3 | -463.93 Thousand USD | -835.36% |
| 2016 FY | -614.68 Thousand USD | -360.03% |
| 2016 Q1 | -16.38 Thousand USD | 52.52% |
| 2016 Q4 | -85.75 Thousand USD | 81.52% |
| 2016 Q2 | -49.6 Thousand USD | -202.75% |
| 2015 Q4 | -34.5 Thousand USD | -24.95% |
| 2015 Q3 | -27.61 Thousand USD | 29.38% |
| 2015 Q1 | -37.42 Thousand USD | -124.86% |
| 2015 Q2 | -39.1 Thousand USD | -4.49% |
| 2015 FY | -133.61 Thousand USD | 39.17% |
| 2014 FY | -219.63 Thousand USD | 96.59% |
| 2014 Q2 | -59.39 Thousand USD | 21.72% |
| 2014 Q1 | -75.87 Thousand USD | 93.07% |
| 2014 Q4 | 150.55 Thousand USD | 163.18% |
| 2014 Q3 | -238.28 Thousand USD | -301.17% |
| 2013 Q4 | -1.09 Million USD | -127.79% |
| 2013 Q3 | -480.76 Thousand USD | 89.22% |
| 2013 Q2 | -4.45 Million USD | -1248.45% |
| 2013 Q1 | -330.67 Thousand USD | 62.91% |
| 2013 FY | -6.45 Million USD | -72.88% |
| 2012 Q4 | -891.43 Thousand USD | -32.48% |
| 2012 FY | -3.73 Million USD | 58.79% |
| 2012 Q2 | -1.08 Million USD | -5.73% |
| 2012 Q3 | -672.86 Thousand USD | 37.93% |
| 2012 Q1 | -1.02 Million USD | 85.3% |
| 2011 FY | -9.05 Million USD | -4501.81% |
| 2011 Q4 | -6.97 Million USD | -1120.1% |
| 2011 Q1 | -914.89 Thousand USD | -1093.12% |
| 2011 Q2 | -698.24 Thousand USD | 23.68% |
| 2011 Q3 | -571.48 Thousand USD | 18.15% |
| 2010 FY | -196.71 Thousand USD | -221.22% |
| 2010 Q3 | -48.18 Thousand USD | -22.56% |
| 2010 Q2 | -39.31 Thousand USD | -22.59% |
| 2010 Q1 | -32.07 Thousand USD | -268.95% |
| 2010 Q4 | -76.68 Thousand USD | -59.13% |
| 2009 Q3 | 235.77 Thousand USD | 601.2% |
| 2009 FY | 162.27 Thousand USD | 103.14% |
| 2009 Q4 | 18.98 Thousand USD | -91.95% |
| 2009 Q2 | -47.04 Thousand USD | -34.28% |
| 2009 Q1 | -35.03 Thousand USD | -102.63% |
| 2008 FY | -5.16 Million USD | -435.54% |
| 2008 Q4 | 1.33 Million USD | 121.32% |
| 2008 Q3 | -6.26 Million USD | -3723.63% |
| 2008 Q2 | -163.72 Thousand USD | -83.53% |
| 2008 Q1 | -89.2 Thousand USD | 94.75% |
| 2007 Q4 | -1.69 Million USD | -574.49% |
| 2007 Q1 | -2091.71 USD | 85.71% |
| 2007 FY | -965.34 Thousand USD | -2998.46% |
| 2007 Q2 | -53.37 Thousand USD | -2451.53% |
| 2007 Q3 | -251.71 Thousand USD | -371.64% |
| 2006 Q2 | -3796.45 USD | 59.19% |
| 2006 Q4 | -14.64 Thousand USD | -385.84% |
| 2006 Q3 | -3013.61 USD | 20.62% |
| 2006 FY | -31.15 Thousand USD | -22.82% |
| 2006 Q1 | -9302.62 USD | -156.62% |
| 2005 FY | -25.36 Thousand USD | 0.0% |
| 2005 Q3 | -21.95 Thousand USD | 0.0% |
| 2005 Q4 | -3625.09 USD | 83.49% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 82.917% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 96.733% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.431% |
| Nascent Biotech, Inc. | -2.08 Million USD | 89.073% |
| Rebus Holdings, Inc. | -1.02 Million USD | 77.635% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.35% |
| Qrons Inc. | -789.34 Thousand USD | 71.099% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 63.927% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.636% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 45.093% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.394% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.696% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 96.531% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 16.56% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.713% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 92.113% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 87.469% |
| Mesoblast Limited | -87.95 Million USD | 99.741% |
| Marizyme, Inc. | -65.34 Million USD | 99.651% |
| Genus plc | 7.9 Million USD | 102.888% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 97.906% |
| Pharming Group N.V. | -10.54 Million USD | 97.837% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 89.486% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 93.851% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 97.421% |
| ContraFect Corporation | -65.15 Million USD | 99.65% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 95.331% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 86.794% |
| IMV Inc. | -36.48 Million USD | 99.375% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 97.17% |
| MultiCell Technologies, Inc. | -380.07 USD | -59922.364% |
| ONE Bio Corp. | 8.67 Million USD | 102.629% |
| Accustem Sciences Inc. | -3.74 Million USD | 93.911% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.559% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 81.997% |
| Q BioMed Inc. | -2.05 Million USD | 88.883% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 93.889% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 90.418% |
| Biomind Labs Inc. | -1.21 Million USD | 81.214% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.618% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 92.645% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 97.113% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 88.297% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -1423.284% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 98.563% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 96.078% |
| GB Sciences, Inc. | -1.36 Million USD | 83.247% |
| Alpha Cognition Inc. | -13.77 Million USD | 98.344% |
| HST Global, Inc. | -146.21 Thousand USD | -56.027% |
| CSL Limited | 2.64 Billion USD | 100.009% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 87.0% |
| Halberd Corporation | -79.67 Thousand USD | -186.318% |
| Enzolytics Inc. | -2.17 Million USD | 89.52% |
| Agentix Corp. | -1.37 Million USD | 83.399% |
| Resverlogix Corp. | -3.61 Million USD | 93.681% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 92.807% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.923% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 332.783% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 103.294% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 94.258% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 92.461% |
| AVAX Technologies, Inc. | -6.41 Million USD | 96.443% |
| Zenith Capital Corp. | -10.59 Million USD | 97.847% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.761% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -881.529% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 94.498% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -277.44% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 88.623% |
| Kadimastem Ltd | -3.3 Million USD | 93.103% |
| Helix BioMedix, Inc. | -1.05 Million USD | 78.398% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 94.027% |
| BioStem Technologies, Inc. | -8.48 Million USD | 97.311% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 48.314% |
| LadRx Corporation | 400.44 Thousand USD | 156.969% |
| Cell Source, Inc. | -5.32 Million USD | 95.713% |
| Regen BioPharma, Inc. | 1.02 Million USD | 122.289% |
| Regen BioPharma, Inc. | 1.02 Million USD | 122.289% |
| NovAccess Global Inc. | -4.76 Million USD | 95.217% |
| Affymax, Inc. | -14.42 Million USD | 98.418% |
| Itoco Inc. | -1.86 Million USD | 87.794% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 94.865% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 86.332% |
| Mobile Lads Corp. | -2.26 Million USD | 89.921% |
| CytoDyn Inc. | -49.84 Million USD | 99.542% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -188.648% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 75.771% |
| SYBLEU INC | -180.3 Thousand USD | -26.524% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 85.855% |
| International Stem Cell Corporation | -131 Thousand USD | -74.143% |
| Bioxytran, Inc. | -4.28 Million USD | 94.67% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -320.34% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 90.984% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.525% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 89.209% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 70.786% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 92.799% |
| Neutra Corp. | -233.46 Thousand USD | 2.286% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 98.876% |
| PureTech Health plc | -65.69 Million USD | 99.653% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 98.927% |
| IXICO plc | -1.17 Million USD | 80.634% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 97.702% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.601% |
| CSL Limited | 2.64 Billion USD | 100.009% |
| Cellectis S.A. | -103.17 Million USD | 99.779% |